United Therapeutics CORP Form 4 insider transactions

Director Christopher Patusky of United Therapeutics Corp. executed stock option exercises and sales on September 3rd and 4th, 2024.

James Edgemond, CFO and Treasurer of United Therapeutics, executed stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock options and sold shares of common stock on August 26, 2024, under a pre-arranged 10b5-1 trading plan.

James Edgemond, CFO and Treasurer of United Therapeutics, exercised stock options and sold shares of common stock on August 26, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on August 22 and 23, 2024, under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales of common stock under a pre-arranged 10b5-1 trading plan on August 20 and 21, 2024.

Director Christopher Causey reported the acquisition and disposal of United Therapeutics Corp [UTHR] common stock on August 21, 2024.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock options and sold shares on August 19, 2024, under a pre-arranged 10b5-1 trading plan.

James Edgemond, CFO and Treasurer of United Therapeutics, exercised stock options and sold shares of common stock on August 19, 2024, according to a Form 4 filing with the SEC.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on August 15 and 16, 2024, under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on August 13 and 14, 2024, under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on August 9 and August 12, 2024, under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales under a pre-arranged 10b5-1 trading plan on August 7th and 8th, 2024.

Michael Benkowitz, President and COO of United Therapeutics, executed stock option exercises and sales on August 7, 2024, involving both direct and indirect ownership through trusts.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales of common stock under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on August 1st and 2nd, 2024, under a pre-arranged 10b5-1 trading plan.

Director Raymond Dwek exercised stock options and sold shares of United Therapeutics Corp (UTHR) on August 2, 2024.

Martine Rothblatt, Chairperson & CEO of United Therapeutics, executed a series of stock option exercises and sales on July 31, 2024, under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on July 29 and 30, 2024, under a pre-arranged 10b5-1 trading plan.

Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales on July 25 and 26, 2024, under a pre-arranged 10b5-1 trading plan.

Director Judy D. Olian reports the acquisition of 1,190 restricted stock units in United Therapeutics Corporation.

Director Richard Giltner reports acquisition of 1,190 restricted stock units in United Therapeutics Corp.

Director Christopher Causey received 1,190 restricted stock units of United Therapeutics Corporation on July 25, 2024, which vest on the one-year anniversary of the grant date.

Director Tommy G. Thompson acquired 2,890 stock options in United Therapeutics Corp on July 25, 2024, as part of an annual non-employee director award.

Director Louis W. Sullivan reports acquisition of stock options and restricted stock units in United Therapeutics Corp.

Director Linda Maxwell reports the acquisition of 2,890 stock options in United Therapeutics Corp.

Director Christopher Patusky reports acquisition of stock options and restricted stock units in United Therapeutics Corp.

Director Nilda Mesa received stock options and restricted stock units as part of an annual non-employee director award from United Therapeutics Corporation.

Director Jan Malcolm reports the acquisition of stock options and restricted stock units in United Therapeutics Corporation.

Director Ray Kurzweil reports the acquisition of stock options and restricted stock units in United Therapeutics Corporation.